Investigating Surprise Signals in the Anterior Insula

May 7, 2024 updated by: Fabienne PICARD, University Hospital, Geneva

Investigating Surprise Signals in the Anterior Insula in Epilepsy Patients With Stereoelectroencephalography Recording

The investigators propose a behavioral experiment with SEEG recording and stimulation, to both confirm the role of a brain region known as the anterior insula in identifying surprise, and disambiguate between competing principles behind adaptation: optimizing and satisficing. Optimizers continue to learn and adapt if performance can be improved, while satisficers are satisfied with a good enough performance and will cease adapting once that is reached.

To study surprise signals in the anterior insula, a brain structure where these signals have been very prominent, the investigators will employ an experiment with subjects who are under SEEG (stereoelectroencephalogram) recording, that is, recording from electrodes which have been surgically implanted in the brain. These recordings will be done as patients perform a task where they try to anticipate the movements of a target on a line in two different learning environments (conditions). The experimenters will then determine whether these signals reflect surprise relative to past engagement with the environment, or surprise that reveals that the agent no longer feels in control because uncertainty is not in line with the reference model. If evidence is consistent with the former, adaptation reflects traditional reinforcement and aims at optimizing behavior. If evidence instead is consistent with the latter, behavior is guided by a prior model (a reference model) and behavior is satisficing.

An fMRI study by d'Acremont and Bossaerts provides initial evidence that activation in the anterior insula supports the satisficing hypothesis, however it lacks the temporal granularity to completely rule out optimizing. In the current project, the investigators propose to use the higher time resolution of SEEG recordings to confirm these findings and reject the optimizing hypothesis.

Additionally, stimulations of the anterior insula during a subset of trials will be used to determine whether insular activation following surprise signals and preceding changes in behavior (learning) is merely correlational or in fact causal. Stimulation will allow us to determine to what extent the subjects' sense of control and subsequent behavior can be influenced in accordance with surprise-based modeling of behavior.

The cohort for this study will be patients with drug-resistant, focal epilepsy and who are hospitalized at the Hôpitaux Universitaires de Genève (HUG) for pre-surgical evaluation of their epilepsy using SEEG. The protocol will run in parallel with the patients' clinical procedures.

Study Overview

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Geneva, Switzerland, 1205
        • Recruiting
        • Service de Neurologie, Dpt des Neurosciences cliniques HUG
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients who suffer from potentially surgically remediable drug-resistant focal epilepsy and require evaluation with intracranial stereo-EEG electrodes and have them implanted in the anterior insula hospitalized at the Hôpitaux Universitaires Genève.

Description

Inclusion Criteria:

  • 18 years or older
  • Fluent in French or English
  • Patient who suffers from potentially surgically remediable drug-resistant focal epilepsy
  • Patient who requires evaluation with intracranial stereo-EEG electrodes and has them implanted in the anterior insula
  • Patient who is able and willing to provide informed consent

Exclusion Criteria:

  • Severe concomitant psychiatric disease or major psychological distress
  • Patients who have an implanted stimulation device (e.g. pacemaker, defibrillator, neurostimulator)
  • Intellectual/neurological/psychiatric deficiencies* or inability to understand or follow the procedure
  • Visual/motor deficiencies which could affect task performance
  • The presence of seizures during routine clinical stimulation of insular electrodes
  • Failure to complete the pre-experiment task training

    • As determined by their clinical evaluation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients

Patients who suffer from potentially surgically remediable drug-resistant focal epilepsy and who require evaluation with intracranial stereo-EEG electrodes and have them implanted in the anterior insula.

N = 10

Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.
Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
Subclinical

Healthy individuals who match the clinical population in age and level of education.

N = 40

Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bias adjustment -- non-stimulation trials (behavioral, numerical)
Time Frame: Up to 2500 ms after stimuli presentation. All data collected during eight 5-minute sessions on the same day
Subjects' choices, measured as the degree of bias correction they employ (a numerical value typically between 0 and +/-3) during outlier trials and the trials immediately following them. These will be quantitatively compared between conditions using Bayes-optimal choices and choices as predicted by Model-Reference Based Adaptive Control.
Up to 2500 ms after stimuli presentation. All data collected during eight 5-minute sessions on the same day
Bias adjustment -- stimulation trials (behavioral, numerical)
Time Frame: Up to 2500 ms after stimuli presentation. All data collected during four 5-minute sessions on the same day
Subjects' choices, measured as the degree of bias correction they employ (a numerical value typically between 0 and +/-3) during stimulation trials (both outlier and non-outlier trials). These will be quantitatively compared to choices on the same trial types without stimulation.
Up to 2500 ms after stimuli presentation. All data collected during four 5-minute sessions on the same day
SEEG-ERP--non-stimulation trials
Time Frame: Up to 2500 ms after stimuli presentation. Averaged over all trials for each task condition. All data collected during 8 5-minute sessions on the same day
Event-related potentials (ERPs) extracted from subjects' stereoelectroencephalographies from intercranial electrodes implanted in the anterior insulae. ERPs will be averaged across the time series and t-statistics will be computed for effect of condition (outlier type).
Up to 2500 ms after stimuli presentation. Averaged over all trials for each task condition. All data collected during 8 5-minute sessions on the same day
SEEG-TF--non-stimulation trials
Time Frame: Up to 2500 ms after stimuli presentation. Averaged over all trials for each task condition. All data collected during 8 5-minute sessions on the same day
The stereoelectroencephalographies from intercranial electrodes implanted in subjects' anterior insulae will be used for time frequency (TF) analyses. Time series components will be extracted for multiple frequencies and t-statistics of the effects of condition (outlier type) will be computed for each frequency.
Up to 2500 ms after stimuli presentation. Averaged over all trials for each task condition. All data collected during 8 5-minute sessions on the same day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reaction time (numerical)
Time Frame: Up to 2500 ms after stimuli presentation. All data collected during 8 5-minute sessions on the same day
Comparison of subjects' response times to stimuli
Up to 2500 ms after stimuli presentation. All data collected during 8 5-minute sessions on the same day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2024

Primary Completion (Estimated)

July 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

June 1, 2023

First Submitted That Met QC Criteria

August 11, 2023

First Posted (Actual)

August 18, 2023

Study Record Updates

Last Update Posted (Actual)

May 8, 2024

Last Update Submitted That Met QC Criteria

May 7, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2022-02041

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on SEEG stimulation

Subscribe